Overview

A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety and effects of a new drug called BMB-101 in people with Prader-Willi Syndrome (PWS). This study is designed as a multi-centre, double-blind, randomized, placebo controlled 2-part study with a blinded main phase followed up an open label extension phase.
Phase:
PHASE2
Details
Lead Sponsor:
Bright Minds Biosciences Pty Ltd